International Journal of Cell Cloning, Vol 7, 242-256, Copyright © 1989 by AlphaMed Press

ORIGINAL ARTICLES

Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies

E Guan, TC Zhou, JH Wang, PG Huang, WP Tang, ML Zhao, Y Chen and YX Sun
Institute of Basic Medical Sciences, Beijing, People's Republic of China.

Monoclonal antibodies (MoAbs) were developed against epidermal growth factor (EGF) receptor on the human epidermoid carcinoma cell line A431. The A431 antigen recognized by the MoAbs has an apparent molecular weight of approximately 170,000, with the same molecular weight as the CNE-2 cell line (poorly differentiated nasopharyngeal carcinoma). Administration of anti-EGF receptor MoAbs inhibited tumor formation, caused by the CNE-2 and A431 cell lines, in athymic mice. When the same MoAbs were used in therapy against Tca8113 (a human tongue carcinoma) and HeLa cells (a human cervical carcinoma), tumor growth was not affected. The number of EGF receptors and the apparent dissociation constants for 125I-EGF on CNE-2 and A431 were 1.3 x 10(5)/cell (Kd 7.7 x 10(-8) M) and 1.4 x 10(6)/cell (Kd 2.4 x 10(-9) M), respectively. Three anti-EGF receptor MoAbs were used in these studies. MoAbs 3 and 176, capable of competing with EGF for receptor binding, showed significant tumor growth inhibition. MoAb 101 was incapable of blocking the binding of EGF to its receptor and was not as effective as MoAbs 3 and 176 in tumor growth inhibition. Our observation is that in vitro, MoAb anti-EGF receptor is cytostatic, rather than cytocidal, against CNE-2 and A431.

This article has been cited by other articles:

				D. Fry, A. Kraker, A McMichael, L. Ambroso, J. Nelson, W. Leopold, R. Connors, and A. Bridges A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science, August 19, 1994; 265(5175): 1093 - 1095. [Abstract] [PDF]